ADVA and PSNC showcase 1200G channel transmission at SC19
19.11.2019 17:45:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it’s hosting a joint showcase with PSNC at SC19 that features the industry’s first 1200Gbit/s optical channel transmission. Built upon the ADVA FSP 3000 TeraFlex™ terminal, the demo underscores the power of adaptive technology to maximize bandwidth efficiency in any network scenario. Using fractional QAM capabilities to boost fiber utilization and channel capacity, the demo highlights how network operators and enterprises can cost-effectively inject capacity into their networks without major upgrades. At SC19, TeraFlex™ will carry 1200Gbit/s channels in a 150GHz window or 800Gbit/s channels in a 100GHz window, delivering an industry-leading spectral efficiency of 8bit/s/Hz. These figures set a new benchmark for a commercially available product. The ADVA FSP 3000 TeraFlex™ has now been shipping for several months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005670/en/
The FSP 3000 TeraFlex™ helps customers inject capacity into their networks without major upgrades (Photo: Business Wire)
“As we approach the Shannon Limit, our compact and open FSP 3000 TeraFlex™ provides an entirely new route to network capacity expansion. This demo reveals how operators can enhance optical paths and reduce cost per bit right now,” said Christoph Glingener, CTO, ADVA. “Transmission terminal design is all about utilizing fiber in the most efficient way, and that’s why our FSP 3000 TeraFlex™ is the high-speed terminal of choice. By providing a 1200Gbit/s channel that consumes only 150GHz of spectrum, we’re leading the industry with spectral efficiency and channel capacity. Compared with the promise of rival 800Gbit/s solutions that are still many months away, we’re delivering 50% more capacity today – and with the added bonus of significantly better reach.”
Presented at SC19, the live demo highlights how spectral efficiency is key to maximizing bandwidth in existing networks. It shows how super-channels in increments of 50GHz are ideal for maximizing client port flexibility while ensuring compatibility with legacy line systems. Using software-defined fractional QAM modulation and adaptive baud rate capabilities, the ADVA FSP 3000 TeraFlex™ can support 1200Gbit/s channels carrying three 400Gbit/s clients or 800Gbit/s channels carrying two 400Gbit/s clients. The reach and spectral efficiency of the dual-core coherent engine implementation is superior to future single-core 800Gbit/s concepts that have reduced client port flexibility and often leave spectrum unutilized.
“Terabit channels are fast becoming essential. Our network enables Europe’s scientific community to share huge data sets and access the most advanced supercomputing applications. But empowering those researchers to stay at the forefront of discovery requires a new level of reach and spectral efficiency. With this demo, we’re showing how mission-critical long-haul networks like ours, which are not fiber-rich, can meet unprecedented data demand,” commented Artur Binczewski, director, Network Division, PSNC. “The ADVA FSP 3000 TeraFlex™ provides the flexibility and granularity needed to squeeze maximum value from our fiber plant. Now we can transmit twelve 100Gbit/s or three 400Gbit/s signals in a single Terabit channel that consumes just 150GHz of spectrum. That level of efficiency enables us to achieve more than we ever thought possible with our DCI network.”
The demo will be on display at SC19 at booth 1955 until Thursday, November 21.
Further details of the demo are available in these slides: https://adva.li/sc19-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About PSNC
Poznan Supercomputing and Networking Center (PSNC) affiliated to the Institute of Bioorganic Chemistry of the Polish Academy of Sciences is an internationally known node of the European Research Area in the field of IT infrastructure of science and an important R&D center in the field of information and communication technologies (ICT). As a development center of e-Infrastructure, PSNC designed and built the Metropolitan Network POZMAN, High Performance Computing Center and the national broadband network PIONIER, maintained and still developed by PSNC. We are an institution of high development potential. A positive consequence of the Centre's exemplary activity in acquiring and implementing projects was the establishment of broad cooperation with international institutions. Projects developed at PSNC include cooperation with 927 units from 59 countries. All projects are focused on IT technology and concern new generation networks, grids, portals, digital libraries, IT energy efficiency, climate, weather, air quality, new sources of energy, digital humanities, personalized medicine, intelligent agriculture, industry 4.0, astronomy, bioinformatics, Big Data analysis, artificial intelligence, New Media, education, Smart City, cyber security. The list of areas of activity in which PSNC undertakes work is constantly expanding, providing an important example of taking up new technological challenges. www.man.poznan.pl/online/en
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005670/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom